Global Last year’s COP28 summit saw a host of pharma players touting their green credentials, as PharmaBoardroom’s Louis Haynes explores here. This is an extract from our Transformative 2023: Regional Pharma Trends report, available for free download now. At the recent COP28 climate change conference in the UAE, industry bodies…
Pharma The CEO of CzechInvest elaborates on the significance of the healthcare and life science industry for the Czech Republic’s transition into an industry 4.0. Furthermore, he reviews what the Czech Republic has to offer for foreign investors over its regional neighbors. Before assuming the position of CEO at CzechInvest you…
Pharma Thierry Guillot, president of Chugai Pharma France, talks about the challenge of transitioning from a small organization, which revolved around one main product into a larger entity capable of delivering multiple products and solutions; he also reveals how since 2008, Chugai and Roche have worked together on marketing and business…
R&D Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through risk mitigation. You founded Transition Therapeutics in 1998. What was the reasoning behind founding a biotech company focused on CNS…
See our Cookie Privacy Policy Here
